Breaking Down The Walgreens Boots Alliance Acquisition - The Special Situations Report Episode #9

Episode Summary

Executive Summary: Episode 9 of Special Situations Report covered a wide range of event-driven catalysts: contested M&A and pre-deal volatility, including Lifeway/Danone litigation and the collapsing 23andMe bid; completed and rumored deals such as Jazz/Chimerix and Sycamore’s Walgreens take-private; notable buybacks and insider buying; Starboard’s campaign at Kenvue; and sudden CEO departures at Kroger, Albertsons, and Green Plains. The hosts emphasized how fragile and opportunistic special situations can be.

Main Topics: Contested and Pre-Deal M&A (Priority: 5/5): The episode opened with updates on several uncertain deal situations, including Danone/Lifeway, 23andMe, QXO/Beacon Roofing Supply, and Howard Hughes. The hosts highlighted how deal terms can shift dramatically when no definitive merger agreement is in place. Announced Acquisitions (Priority: 5/5): Jazz Pharmaceuticals’ acquisition of Chimerix and Sycamore Partners’ take-private of Walgreens Boots Alliance were the major completed/announced transactions discussed. The Walgreens deal structure, including a contingent asset-right tied to VillageMD, received especially detailed treatment. Buybacks and Capital Returns (Priority: 4/5): Two notable repurchase programs stood out: Abercrombie & Fitch’s large buyback and Cinemark’s smaller but meaningful authorization. Park Hotels also featured due to its dividend yield, special dividends, and ongoing repurchases. Insider Buying (Priority: 4/5): The hosts described broad insider buying during market weakness, especially in energy names, and highlighted notable purchases at Fortinet, Park Hotels, and Pebblebrook. They framed insider activity as a useful signal during volatility. Activism at Kenvue (Priority: 3/5): Starboard Value’s proxy campaign against Kenvue was presented as an important activist situation, with signs that board changes may resolve the dispute without a full proxy fight. Leadership Turnover at Kroger, Albertsons, and Green Plains (Priority: 4/5): The sudden exit of Kroger’s CEO, Albertsons’ planned CEO retirement, and Green Plains’ leadership change underscored how major corporate events can overlap with operational and legal stress.

Key Arguments: Pre-deal situations can reprice dramatically when financing, bidder interest, or company cash burn changes; 23andMe was the clearest example of how quickly terms can deteriorate. Danone’s lawsuit against Lifeway shows how legacy agreements, ownership structure, and family disputes can become central deal obstacles. The Jazz/Chimerix deal is unusual because it lacks CVRs despite a clinical-stage biotech profile; the near-term FDA decision may explain that choice. Sycamore’s Walgreens transaction appears more likely to close because financing is in place and the deal structure is carefully designed around VillageMD monetization rights. Insider buying tends to cluster during market stress, and the week’s purchases were interpreted as a constructive signal, especially in energy and REITs. Park Hotels looks attractive because dividend coverage appears adequate and the stock trades below book value, though recession and travel demand remain key risks. Starboard’s campaign at Kenvue may end in compromise if the board adds directors and Jeffrey Smith joins without a prolonged fight. Sudden CEO departures can be tied to non-financial issues, as shown by Kroger, while other exits may reflect a normal transition but still matter in contested industry contexts.

Data Points: Danone initial bid for Lifeway Foods: $25 per share - First offer discussed in the Lifeway/Danone acquisition saga Danone revised bid for Lifeway Foods: $27 per share - Second offer discussed; both were rejected Lifeway trading price: $21.20 per share - Current trading level during the Danone dispute Danone ownership in Lifeway: 23% - Existing stake held by Danone since a 1999 agreement Family stake in Lifeway: nearly 30% - Edward Smolonski and mother Lydmila’s combined stake supporting the deal Julie Smolonski stake in Lifeway: about 18% - CEO ownership stake referenced in the dispute Julie Smolonski equity award: 283,000 shares - Shares granted after Lifeway adopted a poison pill 23andMe original proposed price: $2.53 per share in cash - Initial offer from Anne Wojcicki and New Mountain Capital 23andMe revised offer: $0.41 per share in cash - Wojcicki’s later revised bid after New Mountain withdrew 23andMe trading price: $1.49 per share - Market price versus revised bid 23andMe cash on balance sheet: about $79 million - Liquidity available despite ongoing losses 23andMe quarterly cash burn: more than $40 million per quarter - Used to explain business deterioration QXO tender offer extension date: March 10 - Latest extension of the hostile tender offer for Beacon Roofing Supply QXO tendered shares: about 19% - Portion of Beacon shares tendered so far Howard Hughes standstill date: until March 13 - Special committee’s standstill agreement with Pershing Square Howard Hughes management fee proposal: 1.5% of market cap - Reason cited for the proposal being unacceptable Jazz acquisition of Chimerix: $935 million - Announced purchase price Jazz acquisition price per share: $8.55 per share in cash - Cash consideration for Chimerix shareholders Chimerix premium: over 72% - Premium implied by the announced deal FDA decision date for Dordaviprone: August 18, 2025 - Priority review target date mentioned for Chimerix’s lead drug Walgreens take-private deal size: nearly $24 billion - Sycamore Partners’ announced acquisition of Walgreens Boots Alliance Walgreens cash consideration: $11.45 per share - Cash paid in the Sycamore deal Walgreens contingent right: up to $3 per share - Non-transferable DAP right tied to VillageMD monetization VillageMD ownership by Walgreens: 53% - Walgreens’ stake after the Summit Health and CityMD transaction VillageMD debt to Walgreens: $3.4 billion - Debt expected to be repaid before DAP right holders receive proceeds DAP right payout pool: up to about $2.7 billion - 70% of net proceeds capped at $3 per share Abercrombie & Fitch buyback: $1.3 billion - Large repurchase authorization announced during the week Abercrombie buyback as % of market cap: 30% - Approximate scale of the authorization Cinemark buyback: $200 million - Another notable repurchase announcement Cinemark buyback as % of market cap: about 7% - Scale of the authorization at announcement Fortinet insider purchase: about $34,000 - Director William Newcomb’s purchase Park Hotels insider purchase: 20,000 shares - Director Thomas Eckert’s purchase Park Hotels current price: $11.88 per share - Used to calculate dividend yield Park Hotels annual dividend: $1.00 per share - Based on 25 cents quarterly dividend Park Hotels dividend yield: 8.42% - Yield calculated from annual dividend and share price Park Hotels EPS: $1.02 per share - Referenced for earnings comparison Park Hotels FFO: $2.05 per share - Used to argue dividend coverage Park Hotels share repurchases: about 12% of shares outstanding - Cumulative buybacks over the last three years Kenvue ownership by Starboard: 1.1% - Activist stake in the proxy contest Kroger CEO tenure: over 10 years - Rodney McMullen’s time as CEO before resignation Albertsons CEO tenure: six years - Vivek Sankaran’s service before announcing retirement Green Plains CEO tenure: 17 years - Todd Becker’s length of service before sudden departure Green Plains stock performance during tenure: down about 69% - Share performance cited in discussing the CEO exit

Pivotal Quotes: "So, a little bit of a family feud going on there." — Lamana Suria: Describing the internal conflict among Lifeway shareholders supporting Danone's bid "this new share issuance that Julie got required consent from Danone." — Lamana Suria: Explaining why Danone filed suit against Lifeway and its board "This is one of the risks of pre-deal situations without a definitive merger agreement." — Asif Surya: Reacting to 23andMe’s collapse from a $2.53 offer to a $0.41 revised bid

Implications: Listeners should expect continued volatility in special situations: deal terms can change fast, activist fights can resolve or escalate, and insider buying may offer clues, but execution risk remains high across M&A, spin-offs, and leadership transitions.